Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial
article
OA: closed
CC0
AI-generated summary
Linzagolix demonstrated statistically significant improvement in key secondary endpoints, including non-menstrual pelvic pain and dyschezia, for patients with endometriosis-associated pain in a Phase 3 trial.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
/
My notes (saved in your browser only)
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK